Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
about
Bortezomib in the management of multiple myeloma.Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.Plasma cells as an innovative target in autoimmune disease with renal manifestations.Neurodegeneration Enhances the Development of Arthritis.Post-translational control of T cell development by the ESCRT protein CHMP5.Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activity.The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
P2860
Q34418462-24107239-7A53-4297-8204-DA3F4B759233Q34602046-F65AC406-089D-4506-A624-312CBA6C09EAQ37790694-432CE2F5-FF8A-4722-97A5-540071417F31Q38207937-E34F46AD-48BA-44D2-BF63-B421E82890FEQ38753491-12398C66-BC44-49FB-9289-6176DBBBF88CQ38966578-0B98711D-A572-46D1-8DAF-D4B05B6D601CQ40182044-2A95400A-EC07-4E30-8CF4-5889C8BE8229Q42122199-16EF5804-A5D6-4CC6-96B7-91ED4A88A155Q42738022-457EAB83-DF12-4AFC-930D-9C00E08ED6C4Q43152799-A4D8F045-3274-4D20-84CD-96A6A9496299Q44236379-EA81ED1E-63E2-4E4B-BEB0-226A0AD1566CQ46207877-D15B8D94-5630-464C-8A85-302DFF836BD4Q46797870-79D23C6B-ABE3-4C52-B456-E52240CD7093Q47142177-51CBCA46-DFD0-4C14-AEA7-53A2394D55B1Q53675215-695D04AA-29FE-443D-A0DE-8550F90195BC
P2860
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@en
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@nl
type
label
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@en
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@nl
prefLabel
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@en
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@nl
P2093
P2860
P356
P1476
Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.CDD.4402297
P577
2008-01-11T00:00:00Z
P5875
P6179
1021580753